

August 29, 2018



# SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

JERSEY CITY, N.J., Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor conferences:

- Baird's 2018 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, September 5, 2018 at 2:00 p.m. ET.
- The H.C. Wainwright 20<sup>th</sup> Annual Global Investment Conference at the St. Regis New York on Thursday, September 6, 2018 at 12:30 p.m. ET.
- The Oppenheimer Fall Summit at the Langham, New York, Fifth Avenue on Wednesday, September 26, 2018.

A live webcast of the Baird and HC Wainwright presentations will be available on the Investors section of the Company's website: [www.scynexis.com](http://www.scynexis.com). Replay of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.

## About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida* and *Aspergillus* species. For more information, visit [www.scynexis.com](http://www.scynexis.com).

## CONTACT:

### Investor Relations

Natalie Wildenradt

Argot Partners

Tel: 212-600-1902

[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

### Media Relations

George E. MacDougall

MacDougall Biomedical Communications

Tel: 781-235-3093

[george@macbiocom.com](mailto:george@macbiocom.com)

📄 View original content: <http://www.prnewswire.com/news-releases/scynexis-inc-to-participate-in-upcoming-investor-conferences-300701931.html>

SOURCE SCYNEXIS, Inc.